Emory University

Imperial College of Science, Technology and Medicine

Ashutosh S Jogalekar

Dennis C Liotta

James P Snyder

Anthony G M Barrett

Matthew John Fuchter

Bodo Scheiper

Simak Ali

Raoul Charles Dalmedo Stuart Coombes

Aleksandra Siwicka

Jan Brackow

Matthew J Cook

Sebastian H B Kroll

Processes for the preparation of certain 5,7-diaminopyrazolo[1,5-&#x3b1;]pyrimidine compounds comprising the reaction of a primary or secondary amine and a protected 5-halo-7-aminopyrazolo[1,5-&#x3b1;]pyrimidine compound in solvent system comprising water and one or more organic solvents, optionally in the presence of an exogenous base.

Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds

This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.

Selective inhibitors for cyclin-dependent kinases

Growing community of inventors

Decatur, GA, United States of America

Ashutosh S Jogalekar